| Summary: | A previous CADTH Common Drug Review (CDR) of the use of omalizumab for allergic asthma in 2006 led to the recommendation by the Canadian Expert Drug Advisory Committee that omalizumab not be reimbursed due to: insufficient evidence that omalizumab improves exacerbations that lead to hospitalizations, emergency room (ER) visits, or physician visits; a dearth of data for patients who fail treatment with a long-acting beta2-agonist (LABA) in addition to an inhaled corticosteroids (ICS); and a low likelihood of being cost-effective. The current CDR review was undertaken in response to a request from the drug plans that participate in the CDR review process asking that the use of omalizumab in asthma be re-reviewed in light of the availability of new evidence. Therefore, for the current review, new clinical evidence that has become available since the CDR review in 2006 was considered for inclusion in a systematic review to assess the efficacy and harms of omalizumab in persistent allergic asthma in patients who are inadequately controlled by an ICS in combination with a LABA.
|
|---|